Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
November 04, 2021 07:45 ET
|
Orchard Therapeutics (Europe) Limited
Updates from OTL-201 Clinical Proof-of-Concept Study in MPS-IIIA and OTL-204 Preclinical Study for GRN-FTD at ESGCT Showcase Potential for HSC Gene Therapy in Multiple Neurodegenerative Disorders ...
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
October 13, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European...
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
September 14, 2021 06:00 ET
|
Orchard Therapeutics (Europe) Limited
Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present...
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
September 09, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie...
Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021
September 08, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will webcast a virtual R&D Investor...
Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 07, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard’s Board of...
Orchard Therapeutics to Present at Multiple Investor Conferences in September 2021
September 01, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present and be...
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
August 04, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs New HAE collaboration with Pharming Group highlights broad potential for HSC gene therapy Multiple...
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
July 01, 2021 01:00 ET
|
Orchard Therapeutics (Europe) Limited
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications Reinforces Pharming’s commitment to the HAE community and utilizes its relevant...
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
June 29, 2021 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA Guidance obtained on design of OTL-203 global registrational trial for MPS-IH Enrollment goal...